IgA Nephropathy | Disease Landscape & Forecast | G7 | 2025

Immunoglobulin A nephropathy (IgAN) is an autoimmune disease characterized by the accumulation of IgA in the glomeruli and impaired kidney function. RAAS inhibitors and SGLT-2 inhibitors are widely used for their renoprotective effects. Several novel agents are approved for patients at risk of disease progression: Calliditas Therapeutics’ Tarpeyo / Kinpeygo (delayed-release budesonide), Travere Therapeutics’ dual angiotensin/endothelin receptor antagonist Filspari (sparsentan), Novartis’s complement factor B inhibitor Fabhalta (iptacopan), and Novartis’s endothelin receptor antagonist Vanrafia. Over the forecast period, the IgAN therapy market will experience significant growth owing to the emergence of drugs targeting novel therapeutic pathways, including the complement system (e.g., Alexion’s ravulizumab, Roche’s sefaxersen), B-cell activation pathways (e.g., Otsuka’s Voyxact [sibeprenlimab], Novartis’s zigakibart, Vera Therapeutics’ atacicept, Vertex’s povetacicept), and CD38 targeting monoclonal antibodies (e.g., Biogen’s felzartamab, Takeda’s mezagitamab). Supported by insights from thought leaders, we analyze the challenges and opportunities associated with treating this complex disease.

Questions answered

• What percentage of the IgAN population receives drug treatment? How do physicians use current therapies to treat the disease?
• Where will Tarpeyo / Kinpeygo, Filspari, Fabhalta, and Vanrafia be positioned in the IgAN treatment landscape? Which emerging therapies do experts find most promising, and how will these drugs influence future prescribing patterns?
• What access and reimbursement challenges will emerging therapies face upon market entry?

Scope

• Geography: United States, EU5, Japan
• Primary research: Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research
• Epidemiology: Diagnosed prevalent and drug-treated cases of IgA nephropathy by country and age group
• Forecast: 10-year, annualized, drug-level sales and patient share of key IgA nephropathy therapies through 2034, segmented by brands / generics and epidemiological subpopulations
• Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.